研究業績 2021年

  • Ogura M, Toyoda Y, Sakiyama M, Kawamura Y, Nakayama A, Yamanashi Y, Takada T, Shimizu S, Higashino T, Nakajima M, Naito M, Hishida A, Kawai S, Okada R, Sasaki M, Ayaori M, Suzuki H, Takata K, Ikewaki K, Harada-Shiba M, Shinomiya N, Matsuo H. Increase of serum uric acid levels associated with APOE ε2 haplotype: a clinico-genetic investigation and in vivo approach. Hum Cell 2021 in press. [open access]
  • Kawamura Y, Nakayama A, Shimizu S, Toyoda Y, Nishida Y, Hishida A, Katsuura-Kamano S, Shibuya K, Tamura T, Kawaguchi M, Suzuki S, Iwasawa S, Nakashima H, Ibusuki R, Uemura H, Hara M, Takeuchi K, Takada T, Tsunoda M, Arisawa K, Takezaki T, Tanaka K, Ichida K, Wakai K, Shinomiya N, Matsuo H. A Proposal for Practical Diagnosis of Renal Hypouricemia: Evidence from Genetic Studies of Nonfunctional Variants of URAT1/SLC22A12 among 30,685 Japanese Individuals. Biomedicines 2021 9(8):1012. [open access]
  • Nakayama A, Kawamura Y, Toyoda Y, Shimizu S, Kawaguchi M, Aoki Y, Takeuchi K, Okada R, Kubo Y, Imakiire T, Iwasawa S, Nakashima H, Tsunoda M, Ito K, Kumagai H, Takada T, Ichida K, Shinomiya N, Matsuo H. Genetic-epidemiological analysis of hypouricemia from 4,993 Japanese on nonfunctional variants of URAT1/SLC22A12 gene. Rheumatology 2021 in press. [abstract]
  • Takaoka R, Soejima Y, Guro S, Yoshioka H, Sato H, Suzuki H, Hisaka A. Model-based meta-analysis of changes in circulatory system physiology in patients with chronic heart failure: MBMA of circulatory system physiology in CHF. CPT Pharmacometrics Syst Pharmacol. 2021 in press. [abstract]
  • Nara K, Taguchi A, Tojima Y, Miyamoto Y, Tanikawa M, Sone K, Mori M, Tsuruga T, Yamamoto T, Takenaka R, Takada T, Osuga Y, Suzuki H. History of whole pelvis plus para-aortic radiation is a risk factor associated with febrile neutropenia during chemotherapy for recurrent cervical cancer. Int J Clin Oncol. 2021 in press. [abstract]
  • Taniguchi T, Omura K, Motoki K, Sakai M, Chikamatsu, N, Ashizawa N, Takada T, Iwanaga T. Hypouricemic agents reduce indoxyl sulfate excretion by inhibiting the renal transporters OAT1/3 and ABCG2. Sci Rep. 2021 11(1):7232. [abstract]
  • Toyoda Y, Kawamura Y, Nakayama A, Nakaoka H, Higashino T, Shimizu S, Ooyama H, Morimoto K, Uchida N, Shigesawa R, Takeuchi K, Inoue I, Ichida K, Suzuki H, Shinomiya N, Takada T, Matsuo H. Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12. Rheumatology 2021 in press [abstract]
  • Toyoda Y, Pavelcova K, Bohata J, Jesina P, Kubota Y, Suzuki H, Takada T, Stiburkova B. Identification of two dysfunctional variants in the ABCG2 urate transporter associated with pediatric-onset of familiar hyperuricemia and early-onset gout. Int J Mol Sci. 2021 22(4):1935. [open access]